European Journal of Surgical Oncology
Volume 33 , Pages S1-S4 , December 2007

Increasing long-term survival in advanced colorectal cancer

,Accepted 26 September 2007.

References 

  1. Hughes KS On behalf of the Registry of Hepatic Metastases. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection. Surgery. 1988;103:278–288
  2. Scheele J, Stang R, Altendorf-Hofmann A, et al. Resection of colorectal liver metastases. World J Surg. 1995;19:59–71
  3. Rougier P, Milan C, Lazorthes F, et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Br J Surg. 1995;82:1397–1400
  4. Scheithauer W, Rosen H, Kornek G-V. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J. 1993;306:752–755
  5. Poston GJ, Adam R, Alberts S, et al. Oncosurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol. 2005;23:7125–7134
  6. Abdalla E, Barnett CC, Doherty D, et al. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg. 2002;137:675–680
  7. Vauthey JN, Chaoui A, Do KA, et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery. 2000;127:512–519
  8. Elias D, Liberale G, Vernerey D, et al. Hepatic and extrahepatic colorectal metastases: when respectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol. 2005;12:900–909
  9. Jaeck D. The significance of hepatic pedicle lymph node metastases in surgical management of colorectal liver metastases and of other liver malignancies. Ann Surg Oncol. 2003;10:1007–1011
  10. Nordlinger B, Guiguet M, Vaillant J-C, et al. Surgical resection of colorectal carcinoma metastases to the liver. Cancer. 1996;77:1254 –1262
  11. Fong Y, Fortner J, Sun R, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–316
  12. Figueras J, Valls C, Rafecas J, et al. Resection rates and effect of postoperative chemotherapy on survival after colorectal liver metastases. Br J Surg. 2001;88:980–985
  13. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759–766
  14. Abdalla E, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818–825
  15. Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241:715–722
  16. Kanemitsu Y, Kato T, Hirai T, Yasui K. Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer. Br J Surg. 2004;91:112–120
  17. Elias D, Sideris L, Pocard M, et al. Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol. 2004;11:274–280
  18. Yoshidome H, Ito H, Kimura F, et al. Surgical treatment for extrahepatic recurrence after hepatectomy for colorectal metastases. Hepatogastroenterology. 2004;51:1805–1809
  19. Inoue M, Ohta M, Iuchi K, et al. Benefits of surgery for patients with pulmonary metastases from colorectal cancer. Ann Thorac Surg. 2004;78:238–244
  20. Chiche L. When is first-line resection of hepatic metastases indicated?. Gastroenterol Clin Biol. 2003;27(S2):B11–B13B41–61
  21. Poston GJ. Radiofrequency ablation of colorectal liver metastases: where are we really going?. J Clin Oncol. 2005;23:1342–1344
  22. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229–237
  23. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23–30
  24. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil–leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209–1214
  25. Cals L, Rixe O, Francois E, et al. Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients. Ann Oncol. 2004;15:1018–1024
  26. Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201–1208
  27. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–345
  28. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  29. Ardalan B, Livingstone A, Franceschi D, et al. A phase II study of irinotecan, fluoroxuridine and leucovorin (IFLUX) as first-line chemotherapy in advanced colorectal cancer. J Clin Oncol. 2005;23(16S):270s
  30. Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224:509–520discussion 520–522
  31. Akasu T, Moriya Y, Takayama T. A pilot study of multimodality therapy for initially unresectable liver metastases from colorectal carcinoma: hepatic resection after hepatic arterial infusion chemotherapy and portal embolization. Jpn J Clin Oncol. 1997;27:331–335
  32. Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol. 2001;8:347–353
  33. Giacchetti S, Itzuki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol. 1999;10:663–669
  34. Meric F, Patt YZ, Curley SA, et al. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol. 2000;7:490–495
  35. Shankar A, Leonard P, Renaut AJ, et al. Neo-adjuvant therapy improves respectability rates for colorectal liver metastases. Ann R Coll Surg Engl. 2001;83:85–88
  36. Gil-Delgado MA, Guinet F, Castaing D, et al. Prospective phase II trial of irinotecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer. Am J Clin Oncol. 2001;24:101–105
  37. Wein A, Reidel C, Kockerling F, et al. Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. Ann Oncol. 2001;12:1721–1727
  38. Rivoire M, de Cian F, Meeus P, et al. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer. 2002;95:2283–2292
  39. Miyanari N, Mori T, Takahashi K, Yasuno M. Evaluation of aggressively treated patients with unresectable multiple liver metastases from colorectal cancer. Dis Colon Rectum. 2002;45:1503–1509
  40. Falcone A, Masi G, Cupini S, et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol. 2002;20:4006–4014
  41. Ho WM, Mok TSK, Ma BB, et al. Liver resection after irinotecan (CPT-11), 5-fluorouracil (5FU) and folinic acid (FA) in patients (pts) with unresectable liver metastases (Mets) from colorectal cancer (CRC). Proc Am Soc Clin Oncol. 2003;22:312
  42. Alberts SR, Donohue JH, Mahoney MR, et al. Liver resection after 5-fluorouracil, leucovorin and oxaliplatin for patients with metastatic colorectal cancer (MCRC) limited to the liver. A North Central Cancer Treatment Group (NCCTG) phase II study. Proc Am Soc Clin Oncol. 2003;22:263
  43. Zelek L, Bugat R, Cherqui D, et al. Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). Ann Oncol. 2003;14:1537–1542
  44. Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal carcinoma patients. Ann Oncol. 2004;15:933–939
  45. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644–657
  46. Rougier P, Raoul J-L, van Laethem J-L, et al. Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal cancer. Proc Am Soc Clin Oncol. 2004;22:248
  47. Tabernero JM, van Cutsem E, Sastre J, et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer expressing epidermal growth factor receptor (EGFR): preliminary results. Proc Am Soc Clin Oncol. 2004;22:248
  48. de la Camara J, Rodriguez J, Rotellar F, et al. Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer. Proc Am Soc Clin Oncol. 2004;23:268
  49. Leonard GS, Fong Y, Jarnagin W, et al. Liver resection after hepatic infusion (HAI) plus systemic oxaliplatin (OXAL) combination in pretreated patients with extensive unresectable colorectal liver metastases. Proc Am Soc Oncol. 2004;23:256
  50. Falcone A, Masi G, Cupini S, et al. Surgical resection of metastases (mts) after biweekly chemotherapy with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI) in initially unresectable metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol. 2004;23:258
  51. Fisher GA, Kuo T, Cho CD, et al. A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol. 2004;23:249
  52. Gruenberger T, Schuell B, Kornek G, Scheithauer W. Neoadjuvant chemotherapy for resectable colorectal cancer metastases: impact on magnitude of liver resection and survival. Proc Am Soc Clin Oncol. 2004;23:270
  53. Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. October 17, 2005;23:9243–9249
  54. Diaz-Rubio E, Tabernero J, van Cutsem E, et al. Cetuximiab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international phase II study. J Clin Oncol. 2005;23(16S):254s
  55. Abad A, Anton A, Massuti B, et al. Resectability of liver metastases (LM) in patients with advanced colorectal cancer (ACRA) after treatment with the combination of oxaliplatin (OXA), irinotecan (IRI) and 5FU. Final results of a phase II study. J Clin Oncol. 2005;23(16S):275s
  56. Bouchahda M, Tanaka K, Adam R, et al. Three-drug chemotherapy via hepatic artery as salvage treatment for patients with liver-only metastases from colorectal cancer. J Clin Oncol. 2005;23(16S):175s
  57. Martoni A, Pinto C, di Fabio F, et al. Phase II randomized trial on protracted 5-fluorouracil infusion plus oxaliplatin (FOX) versus capecitobine plus oxaliplatin (XELOX) as first-line treatment in advanced colorectal cancer (ACRC): preliminary results of the Italian FOCA study. J Clin Oncol. 2005;23(16S):275s
  58. Moosmann N, Kern W, Waggershausser T, et al. Hepatic artery infusion of 5-fluorouracil, folinic acid plus oxaliplatin for liver metastases from colorectal cancer. Final analysis of a phase I/II study. J Clin Oncol. 2005;23(16S):278s
  59. Folprecht G, Lutz MP, Seufferlein T, et al. Cetuximab and irinotecan/5-FU/FA (AIO) as first line treatment in metastatic colorectal cancer (mCRC): final results and pharmacokinetic data of a phase I/IIa study. J Clin Oncol. 2005;23(16S):281s
  60. Sufferlein T, Dittrich C, Riemann J, et al. A phase I/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR). Preliminary results. J Clin Oncol. 2005;23(16S):281s
  61. Garassino I, Carnaghi C, Rimassa L, et al. Definitive results of hybrid chemotherapy with intravenous (iv) oxaliplatin (OXA) and folinic acid (FA), and intra-hepatic infusion (HAI) of 5-fluorouracil (5-FU) in patients with colorectal liver metastases. J Clin Oncol. 2005;23(16S):288s
  62. Shimonov M, Hayat H. Alternating hepatic artery chronotherapy with CPT-11 and systemic chronotherapy with 5-FU/FA+carboplatin for metastatic colorectal cancer confined to the liver: a phase II study. J Clin Oncol. 2005;23(16S):297s
  63. Seium Y, Stupp R, Ruhstaller T, et al. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I–II study. Ann Oncol. 2005;16:762–766
  64. Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005;16:1311–1319
  65. Elias D, Youssef O, Sideris L, et al. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol. 2004;86:4–9
  66. Schrag D, Weiser M, Schattner M, et al. An increasingly common challenge: management of the complete responder with multi-focal metastatic colorectal cancer. J Clin Oncol. 2005;23:1799–1802
  67. Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases. Ann Surg. 2004;240:1052–1061
  68. Vauthey J-N, Abdalla EK. Unresectable hepatic colorectal metastases: need for new surgical strategies. Ann Surg Oncol. 2006;13:5–6

PII: S0748-7983(07)00556-2

doi: 10.1016/j.ejso.2007.09.020

European Journal of Surgical Oncology
Volume 33 , Pages S1-S4 , December 2007

Article Tools